📊 JUNS Key Takeaways
Is Jupiter Neurosciences, Inc.. (JUNS) a Good Investment?
Jupiter Neurosciences exhibits critical financial distress with negative stockholders' equity of -$2.8M (technical insolvency), severe liquidity crisis (current ratio 0.51x), and an unsustainable burn rate of $1.4M per period with only $2.4M cash remaining. Minimal revenue of $18.7K with zero YoY growth and accelerating losses indicate the company lacks commercial traction and faces imminent solvency concerns absent immediate capital infusion.
Fundamentals are extremely weak: negligible revenue with worsening losses and negative stockholders’ equity indicate a fragile, unsustainable position. Liquidity is tight (0.65x current ratio) and operating cash burn of $5.41M exceeds the $3.79M cash balance, implying imminent financing needs and likely dilution. Without meaningful revenue growth or expense reduction, the path to profitability remains unclear.
Why Buy Jupiter Neurosciences, Inc.. Stock? JUNS Key Strengths
- Maintains $2.4M in cash reserves providing 1.7-2 periods of operational runway
- No long-term debt obligations on balance sheet
- Gross margin of 76.6% demonstrates potential economics if commercial success achieved
- High gross margin on limited revenue base
- No long-term debt reduces interest burden
- Cash and equivalents of $3.79M provide short-term runway
JUNS Stock Risks: Jupiter Neurosciences, Inc.. Investment Risks
- Negative stockholders' equity of -$2.8M: liabilities exceed assets by $2.8M indicating technical insolvency
- Critical liquidity crisis with current ratio 0.51x unable to cover short-term obligations
- Operating cash burn of -$1.4M per period with only 1.7-2 periods of cash runway at current burn rate
- Revenue stagnant at $18.7K with 0% YoY growth indicating failed commercialization and pipeline challenges
- Net income declining 254% YoY demonstrating rapid financial deterioration
- Zero insider Form 4 activity in past 90 days suggesting management lacks confidence in turnaround
- As early-stage biotech, survival dependent on successful capital raise; failed clinical or regulatory outcomes would be fatal
- Negative stockholders’ equity and potential going-concern risk
- Sustained operating losses and heavy cash burn
- Weak liquidity (0.65x current ratio) and high dilution/financing risk
Key Metrics to Watch
- Cash balance and burn rate trend - determines runway until next capital raise necessity
- Revenue growth trajectory - any signs of commercial traction or contract wins
- Operating loss trend - whether burn rate is accelerating or stabilizing
- Stockholders' equity recovery - ability to return to positive equity position
- Capital raises and dilution - terms of survival funding will heavily dilute existing shareholders
- Operating cash flow
- Stockholders’ equity
Jupiter Neurosciences, Inc.. (JUNS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
JUNS Profit Margin, ROE & Profitability Analysis
JUNS vs Healthcare Sector: How Jupiter Neurosciences, Inc.. Compares
How Jupiter Neurosciences, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Jupiter Neurosciences, Inc.. Stock Overvalued? JUNS Valuation Analysis 2026
Based on fundamental analysis, Jupiter Neurosciences, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Jupiter Neurosciences, Inc.. Balance Sheet: JUNS Debt, Cash & Liquidity
JUNS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Jupiter Neurosciences, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.08 indicates the company is currently unprofitable.
JUNS Revenue Growth, EPS Growth & YoY Performance
JUNS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$1.5M | $-0.05 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Jupiter Neurosciences, Inc.. Dividends, Buybacks & Capital Allocation
JUNS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Jupiter Neurosciences, Inc.. (CIK: 0001679628)
📋 Recent SEC Filings
❓ Frequently Asked Questions about JUNS
What is the AI rating for JUNS?
Jupiter Neurosciences, Inc.. (JUNS) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are JUNS's key strengths?
Claude: Maintains $2.4M in cash reserves providing 1.7-2 periods of operational runway. No long-term debt obligations on balance sheet. ChatGPT: High gross margin on limited revenue base. No long-term debt reduces interest burden.
What are the risks of investing in JUNS?
Claude: Negative stockholders' equity of -$2.8M: liabilities exceed assets by $2.8M indicating technical insolvency. Critical liquidity crisis with current ratio 0.51x unable to cover short-term obligations. ChatGPT: Negative stockholders’ equity and potential going-concern risk. Sustained operating losses and heavy cash burn.
What is JUNS's revenue and growth?
Jupiter Neurosciences, Inc.. reported revenue of $18.7K.
Does JUNS pay dividends?
Jupiter Neurosciences, Inc.. does not currently pay dividends.
Where can I find JUNS SEC filings?
Official SEC filings for Jupiter Neurosciences, Inc.. (CIK: 0001679628) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is JUNS's EPS?
Jupiter Neurosciences, Inc.. has a diluted EPS of $-0.06.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is JUNS a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Jupiter Neurosciences, Inc.. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is JUNS stock overvalued or undervalued?
Valuation metrics for JUNS: ROE of N/A (sector avg: 15%), net margin of -11,054.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy JUNS stock in 2026?
Our dual AI analysis gives Jupiter Neurosciences, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is JUNS's free cash flow?
Jupiter Neurosciences, Inc..'s operating cash flow is $-1.4M, with capital expenditures of N/A. FCF margin is -7,678.0%.
How does JUNS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -11,054.9% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.51 (avg: 2).